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Evaluation of nonclassic CF is complicated by inhomogeneous standardisation of
sweat test methods despite the presence of consensus criteria. Aim of this study
was to investigate the interpretation of sweat test parameters and its correlation to
intestinal CFTR chloride secretion and CFTR genotype.
In n = 103 patients (mean age 11±1 yrs.) with mild pulmonary symptoms, PS
and 0−1 mutations in CFTR mutation screening a non-standardised sweat test
(Cl− concentration without sweat amount/Na+ concentration/conductivity) in the
collaborating center had been interpretated as pathological/borderline, in part due
to ignorance of reference values. We compared these data with a standardised sweat
test and both intestinal current measurement (ICM) (n = 103) and extensive CFTR
genotype analysis (exon 1−27) (n = 29).
Present sweat test results (Cl− standardised 40±2mmol/l) differed signiﬁcantly
from previous recordings: Cl− non-standardised 61±3mmol/l (p< 0.001), Na+
70±5mmol/l, NaCl 74±3mmol/l. On the basis of ICM and CFTR genotype analysis
the diagnosis nonclassic CF was made in n = 7 individuals with rare mutations.
Interestingly, in all n = 14 patients who already had been diagnosed and treated for
CF for up to 30 years before inclusion into this study, a revision of the diagnosis
CF was necessary.
These data underline the problem of non-standardised sweat test performance and
the importance of adequate result interpretation. This could avoid unnecessary
extended diagnostics and misdiagnosing of CF. ICM helps to overcome diagnostic
dilemmas by exclusion or conﬁrmation of nonclassic CF when needed.
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This study aimed to describe the outcome of the fetuses in whom an echogenic
bowel was detected at routine ultrasound examinations of pregnancies in Brittany
over a 15-year period (1991–2005). We registered all the diagnoses of echogenic
bowel made in pregnant women living in Brittany and who were referred for a CFTR
gene analysis (n = 269). A questionnaire was sent to the gynaecologists to know the
pregnancy outcome and the pathologies diagnosed. We calculated the CF frequency,
described the other pathologies and assessed the ability of ultrasonography to detect
CF in utero. Among the 269 fetuses, 21 were diagnosed with CF, leading to a CF
incidence of 7.8%. The pregnancy outcome was documented for 212 of the non-CF
fetuses (85.5%) and an other pathology was evidenced in 46 of them (21.7%). A
karyotypic abnormality was diagnosed in 21.7% of these fetuses (n = 10 including
7 Trisomy 21), a congenital viral infection in 19.6% (n = 9 including 4 CMV)
and a cardiac malformation in 15.2% (n = 7). The other diagnoses were: atresia
(n = 4), toxemia gravidis (n = 3) and other (n = 13 including 7 abdominal problems).
Finally, by combining these data with those of the newborn screening, we showed
that ultrasonography enabled to diagnose 10.2% of the CF cases over the study
period. These ﬁndings are of ﬁrst importance for clinicians who order testing for
CF following the diagnosis of an echogenic bowel. They show that a pathology was
diagnosed in 28.8% of such fetuses and highlight the ability of ultrasonography to
detect CF in utero.
Supported by: Association “Vaincre La Mucoviscidose”.
373* Respiratory exacerbations in childhood associated with
compound heterozygote CFTR genotype DF508/R117H on a
background of 7T polythymidine tract at intron 8
T.W. Lee1, S.P. Conway1,2, D. Peckham2, K.G. Brownlee1. 1Leeds Regional
Paediatric Cystic Fibrosis Centre, St James’s University Hospital, Leeds, United
Kingdom; 2Leeds Regional Adult Cystic Fibrosis Centre, Seacroft Hospital, Leeds,
United Kingdom
Debate continues regarding the clinical implications for compound heterozygotes
identiﬁed with DF508 and R117H/7T mutations of the CFTR gene. Consequently it
remains unclear whether R117H/7T mutations should be screened for, how intensive
monitoring and treatment should be, and what information about prognosis should
be given.
Previous reports regarding children with this genotype have shown that pathogenic
organisms such as Pseudomonas aeruginosa and Staphylococcus aureus are com-
monly isolated from respiratory secretions [1,2] and there is one recent report of a
pulmonary exacerbation in childhood associated with DF508/R117H/7T [2].
We report extensive and prolonged right middle lobe and right lower lobe col-
lapse and bilateral patchy consolidation in a 4 year-old child with this genotype.
Bronchoscopy two months after the start of the illness demonstrated extensive pus
in the right main stem bronchus. Culture of respiratory secretions was positive
for Staphylococcus aureus. Symptoms and chest X-ray changes resolved after three
weeks treatment with physiotherapy and intravenous antibiotics. Subsequently Pseu-
domonas aeruginosa has been isolated from her sputum during a mild respiratory
exacerbation.
Taken together with recent published data [1,2] this case would suggest that this
compound heterozygote CF mutation should not be considered benign in childhood.
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Progressive pulmonary disease associated with chronic bacterial infection and
inﬂammation is the major cause of morbidity and mortality in cystic ﬁbrosis
(CF) patients. Identifying markers of inﬂammation that correlate with lung injury
may be useful in monitoring disease progression and response to therapy. High
resolution computed tomography (HRCT) is used to monitor changes in lung
structure but does not permit differentiation between acute and chronic lesions.
We have previously shown that positron emission tomography (PET) with 18ﬂuoro-
deoxy-glucose (FDG) allows visualization of focal inﬂammation or infection and
therefore appears to be a promising tool to quantify new processes.
The purpose of this study was to determine whether biomarkers of systemic
inﬂammation correlate with FDG-PET/CT ﬁndings.
14 patients with CF (12 male, 2 female, age 14−40 y) performed FDG-PET/CT.
PET and CT images were interpreted by a nuclear medicine physician/radiologist,
blinded to the clinical data. We correlated the PET severity score (PSS), reﬂecting
the number and intensity of FDG uptake of lung foci with FEV1, CRP, WBC, %
and total neutrophils and sputum bacteriology.
The best correlation was detected between PSS and total neutrophils (R2 = 0.4),
no correlation was noted between PSS and CRP (R2 = 0.1), WBC (R2 = 0.19), %
neutrophils (R2 = 0.06) or FEV1 (R
2 = 0.2).
Our ﬁndings suggest that the focal changes observed in FDG-PET correlate with
increased total neutrophils count, reﬂecting active neutrophilic inﬂammation. Larger
studies, currently carried out at our center, are needed to validate these results.
Conﬁrmation may add FDG-PET/CT as a method to predict the severity of disease
progression in patients with CF.
